

Available online at www.sciencedirect.com

Resuscitation

journal homepage: www.elsevier.com/locate/resuscitation

Editorial

Interpreting observational data on adrenaline in cardiac arrest is complicated



The International Liaison Committee on Resuscitation (ILCOR) currently suggests routine administration of 1 mg of adrenaline every 3–5 min (undefined maximum) during cardiac arrest resuscitation until return of spontaneous circulation (ROSC) or termination of resuscitation; however, the available science supporting this recommendation is limited.¹ The effects of adrenaline are complex. In animal studies, adrenaline administration during cardiopulmonary resuscitation (CPR) is effective at improving coronary perfusion²; however, adrenaline also leads to cerebral vasoconstriction and decreased oxygenation, potentially leading to secondary neurological damage and brain death.^{3,4} Randomized controlled trials (RCTs) and large observational studies suggest that higher cumulative doses of adrenaline improve short-term outcomes but not long-term outcomes.^{5–7}

In this issue of *Resuscitation*, Fothergill et al. report the association of repeated doses of adrenaline with decreased survival in out-of-hospital (OHCA) patients resuscitated by the London Ambulance Service in the United Kingdom.⁸ This study does not resolve the controversy but rather adds to previous observational studies suggesting potential harm of adrenaline. Prior observational studies reported decreasing survival with higher total doses of adrenaline.^{9,10} There are several issues to consider in interpreting the current study.⁸

The study population in the current study included patients with initial ventricular fibrillation or pulseless ventricular tachycardia (VF/pVT), pulseless electrical activity (PEA) and asystole. This population is highly heterogeneous with different etiologies of cardiac arrest, different survival rates and different potential effects of epinephrine. Patients with VF/pVT are more likely to have a cardiac etiology and better survival outcomes whereas patients with PEA and asystole have heterogeneous etiologies and very poor outcomes. In the recent PARAMEDIC2 RCT comparing adrenaline to placebo, adrenaline improved overall survival up to 3 months; however, these positive results were mainly driven by patients with non-shockable rhythms, not with VF/pVT.¹¹ Although the current study was likely limited in sample size to perform subgroup analyses, its results may conflate the effects of adrenaline in different patient populations and conditions.⁸

The study also included patients who received adrenaline either by intravenous (IV) or intraosseous (IO) routes. The clinical effects and implications of receiving adrenaline by IO compared to IV are not the same. Although the practice of IO access in OHCA, particularly in the tibia, for administering fluids and medications has increased over time due to perceived rapidity, ease and effectiveness,^{12,13} previous studies have shown that patients treated using IO had worse outcomes compared to IV.^{14,15} This may be due to confounders

related to establishing IO over IV access; IO is often an alternate approach when unable to establish IV in patients who are difficult to resuscitate. In swine studies, tibial IO administration of adrenaline showed a significantly longer time to reach peak blood concentrations.¹⁶ The effect of the various routes of adrenaline administration on patient outcomes was not clear in the current study.

The timing of adrenaline administration is also a major confounder in all observational studies. The resuscitation protocol used by the London Ambulance Service in the current study was to administer adrenaline only after three unsuccessful defibrillation attempts for VF/pVT. This may not be generalizable to other emergency medical systems (EMS) where adrenaline is administered earlier in resuscitation. Delayed adrenaline administration also complicates the interpretation of the results, as the time from EMS call to first adrenaline dose will be longer compared to other EMS agencies. Studies have found an association between delays to adrenaline administration and decreased survival.^{17,18} There are no RCTs on the timing of adrenaline in cardiac arrest. Similar to the current study, the mean time to adrenaline administration in the PARAMEDIC2 RCT was 21 min after call to 911,¹¹ suggesting that the drug was provided too late to have a positive effect on neurological outcomes.

ILCOR recently published a consensus statement on core outcomes for effectiveness trials, which include survival, neurological outcomes and quality of life measures.¹⁹ Although the consensus statement was not primarily intended for observational studies, there is a need to better understand the effects of repeated doses of adrenaline on outcomes beyond survival. In the largest cohort study to date, there was an increased odds of mortality and poor neurologic function one month post-arrest with prehospital administration of adrenaline in a propensity matched analysis.⁶ Nevertheless, all observational studies are unable to account for unmeasured or unmeasurable confounders, making interpretation of these studies difficult. Furthermore, observational studies on the cumulative dose of adrenaline are plagued by confounding and “resuscitation time bias” making it necessary to perform RCTs to answer this specific research question and knowledge gap.²⁰ To address this, the Canadian Resuscitation Outcomes Consortium (CanROC) will be leading an RCT to evaluate a low cumulative dose of adrenaline in OHCA resuscitation. The **Epinephrine Dose: Optimal versus Standard Evaluation (EpiDOSE)** trial is a multicentre, double-blinded RCT across sites in Canada evaluating a low cumulative dose (2 mg maximum) compared to the current standard (undefined maximum) dose of adrenaline (NCT03826524).

The study by Fothergill et al. adds important data to the controversial literature of adrenaline in cardiac arrest.⁸ Due to the inherent limitations of interpreting data in observational cardiac arrest studies, there is a need for clinical trials to evaluate the cumulative dose of adrenaline during OHCA resuscitation.

Disclosures

S.L. and P.D. are Principal Investigators of a Canadian Institutes of Health Research Project Grant for a clinical trial to evaluate low dose adrenaline during cardiac arrest resuscitation (NCT03826524). S.L. was an Evidence Reviewer for the C2015 ILCOR advanced life support taskforce.

REFERENCES

1. Soar J, Callaway CW, Aibiki M, et al. Part 4: Advanced life support: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Resuscitation* 2015;95:e71–120.
2. Paradis NA, Martin GB, Rosenberg J, et al. The effect of standard- and high-dose epinephrine on coronary perfusion pressure during prolonged cardiopulmonary resuscitation. *JAMA* 1991;265:1139–44.
3. Ristagno G, Tang W, Huang L, et al. Epinephrine reduces cerebral perfusion during cardiopulmonary resuscitation. *Crit Care Med* 2009;37:1408–15.
4. Nosrati R, Lin S, Mohindra R, Ramadeen A, Toronov V, Dorian P. Study of the effects of epinephrine on cerebral oxygenation and metabolism during cardiac arrest and resuscitation by hyperspectral near-infrared spectroscopy. *Crit Care Med* 2019, doi:<http://dx.doi.org/10.1097/CCM.0000000000003640>.
5. Lin S, Callaway CW, Shah PS, et al. Adrenaline for out-of-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials. *Resuscitation* 2014;85:732–40.
6. Nagihara A, Hasegawa M, Abe T, Nagata T, Wakata Y, Miyazaki S. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. *JAMA* 2012;307:1161–8.
7. Goto Y, Maeda T, Goto Y. Effects of prehospital epinephrine during out-of-hospital cardiac arrest with initial non-shockable rhythm: an observational cohort study. *Crit Care* 2013;17:R188.
8. Fothergill RT, Emmerson AC, Iyer R, et al. Repeated adrenaline doses and survival from an out-of-hospital cardiac arrest. *Resuscitation* 2019;138:316–21.
9. Glover BM, Brown SP, Morrison L, et al. Wide variability in drug use in out-of-hospital cardiac arrest: a report from the resuscitation outcomes consortium. *Resuscitation* 2012;83:1324–30.
10. Kaji AH, Hanif AM, Bosson N, Ostermayer D, Niemann JT. Predictors of neurologic outcome in patients resuscitated from out-of-hospital cardiac arrest using classification and regression tree analysis. *Am J Cardiol* 2014;114:1024–8.
11. Perkins GD, Ji C, Deakin CD, et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2018;379:711–21.
12. Reades R, Studnek JR, Vandeventer S, Garrett J. Intraosseous versus intravenous vascular access during out-of-hospital cardiac arrest: a randomized controlled trial. *Ann Emerg Med* 2011;58:509–16. Gazin N, Auger H, Jabre P, et al. Efficacy and safety of the EZ-IO intraosseous device: Out-of-hospital implementation of a management algorithm for difficult vascular access. *Resuscitation* 2011;82:126–9.
13. Feinstein BA, Stubbs BA, Rea T, Kudenchuk PJ. Intraosseous compared to intravenous drug resuscitation in out-of-hospital cardiac arrest. *Resuscitation* 2017;117:91–6.
14. Kawano T, Grunau B, Scheuermeyer FX, et al. Intraosseous vascular access is associated with lower survival and neurologic recovery among patients with out-of-hospital cardiac arrest. *Ann Emerg Med* 2018;71:588–96.
15. Hoskins SL, do Nascimento Jr. P, Lima RM, Espana-Tenorio JM, Kramer GC. Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. *Resuscitation* 2012;83:107–12.
16. Nakahara S, Tomio J, Nishida M, Morimura N, Ichikawa M, Sakamoto T. Association between timing of epinephrine administration and intact neurologic survival following out-of-hospital cardiac arrest in Japan: a population-based prospective observational study. *Acad Emerg Med* 2012;19:782–92.
17. Tanaka H, Takyu H, Sagisaka R, et al. Favorable neurological outcomes by early epinephrine administration within 19 minutes after EMS call for out-of-hospital cardiac arrest patients. *Am J Emerg Med* 2016;34:2284–90.
18. Haywood K, Whitehead L, Nadkarni VM, et al. COSCA (core outcome set for cardiac arrest) in adults: an advisory statement from the international liaison committee on resuscitation. *Circulation* 2018;137:e783–801.
19. Andersen LW, Grossestreuer AV, Donnino MW. “Resuscitation time bias”—A unique challenge for observational cardiac arrest research. *Resuscitation* 2018;125:79–82.

Steve Lin^{a,b,c,*}

^aDepartment of Emergency Medicine, St. Michael's Hospital, Toronto, Ontario, Canada

^bDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada

^cInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

Paul Dorian^{b,d}

^bDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada

^dDivision of Cardiology, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada

* Corresponding author at: St. Michael's Hospital, Department of Emergency Medicine, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.

E-mail address: LinS@smh.ca (S. Lin).

<http://dx.doi.org/10.1016/j.resuscitation.2019.02.036>

© 2019 Elsevier B.V. All rights reserved.